Exploring the impact of controlled substance restrictions on epilepsy care in the United States: A neurologist survey
Epilepsy & Behavior · 2026-11 · 184 · 111229
DOI: 10.1016/j.yebeh.2026.111229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2026-11. Verfasst von Lia de Leon Ernst und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Department of Neurology, USA; Portland VA Medical Center, Department of Neurology, USA. Electronic address: ernst…. Hauptthemen laut MEDLINE: Epilepsy, Neurologists, Anticonvulsants, Controlled Substances. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
RATIONALE: Access to anti-seizure medications (ASMs) is critically important to patients with epilepsy (PWE), given that missed doses can lead to breakthrough seizures, morbidity, or mortality. Numerous ASMs are subject to U.S. Drug Enforcement Administration (DEA) scheduling regulations. Controlled substance restrictions present barriers to timely medication access. Scheduling restricts ASM access in myriad ways: biometric data and/or physical signature requirements, refill-too-soon policies, and mail-order availability may be restricted. We hypothesized that ASM misuse is rare, but there is sparse literature available regarding real-world ASM use and clinical impact of restrictions. This survey study investigates whether ASM restrictions impact patient care and whether neurologists encounter patient misuse of ASMs in common practice. METHODS: An anonymous IRB-approved electronic survey was directly distributed to neurologists and neurology clinicians who treat adult patients with epilepsy via email as well as indirectly via national neurology organization platforms. RESULTS: 236 participants completed the survey. 82% of respondents reported treating primarily PWE. 99% of participants reported having patients experience delayed ASM refills due to restrictions, and 96% reported breakthrough seizures among patients due to scheduled ASM restrictions. Perceived patient misuse of ASMs was generally low. There was a stark difference in reported misuse rates comparing clobazam to traditional benzodiazepines, with 8% reporting rare or occasional misuse of clobazam versus 79% reporting rare or occasional misuse of traditional benzodiazepines. Perceived misuse of non-benzodiazepine, non-gabapentinoid ASMs was very rare; 1% of participants perceived any instances of misuse with brivaracetam or lacosamide, and 0% reported any misuse with perampanel or cenobamate. CONCLUSIONS: Respondents reported high rates of medication access issues related to controlled substance restrictions and low rates of ASM misuse. Controlled substance restrictions create practical barriers to reliably obtaining scheduled ASM prescriptions that can result in increased risk of morbidity and mortality. Controlled substance restrictions warrant reevaluation for PWE given the specific risk-benefit tradeoffs for this life-threatening neurologic condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University, Department of Neurology, USA; Portland VA Medical Center, Department of Neurology, USA. Electronic address: ernst@ohsu.edu.
- Oregon Health & Science University, Department of Neurology, USA.
- Oregon Health & Science University, Department of Neurology, USA; Portland VA Medical Center, Department of Neurology, USA.
Zitieren
APA
de Leon Ernst, L., Simon, A., Datta, P., Das, R., & Spencer, D. C. (2026). Exploring the impact of controlled substance restrictions on epilepsy care in the United States: A neurologist survey. Epilepsy & Behavior, 184, 111229. https://doi.org/10.1016/j.yebeh.2026.111229
Vancouver
de Leon Ernst L, Simon A, Datta P, Das R, Spencer DC. Exploring the impact of controlled substance restrictions on epilepsy care in the United States: A neurologist survey. Epilepsy & Behavior. 2026;184:111229. doi:10.1016/j.yebeh.2026.111229
BibTeX
@article{deLeonErnst2026,
author = {de Leon Ernst, Lia and Simon, Amanda and Datta, Proleta and Das, Rohit and Spencer, David C},
title = {Exploring the impact of controlled substance restrictions on epilepsy care in the United States: A neurologist survey},
journal = {Epilepsy & Behavior},
year = {2026},
volume = {184},
pages = {111229},
doi = {10.1016/j.yebeh.2026.111229}
}
EUVIMED